Novo Nordisk intends to appeal adverse ruling in Prandin® (repaglinide) patent case
2011-01-19 · Novo Nordisk A/S · original novonordisk.com ↗
Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable. Novo Nordisk markets repaglinide under the trade name Prandin® and a fixed dose repaglinide/metformin tablet under the trade name PrandiMet®. The district court ruling has the potential to facilitate launch of a generic repaglinide. At present, it is unclear whether or when a generic version of Prandin® or PrandiMet® will be available in the U.S. market. Novo Nordisk intends to appeal this ruling and is evaluating its best options for doing so. Further information: Media: Investors: Mike Rulis Klaus Bülow Davidsen Tel: (+45) 3079 3573 Tel: (+45) 4442 3176 [email protected] [email protected] Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 [email protected] Jannick Lindegaard Tel: (+45) 4442 4765 [email protected] In North America: In North America: Ken Inchausti Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 [email protected] [email protected] Company Announcement no 2 / 2011
The release as fetched from its publisher. novonordisk.com ↗